This review compiles the current knowledge on the effects of prostanoids -arachidonic acid metaboliteson their own synthesis, activity and degradation. Interaction mechanisms between the receptors for the relevant compounds are presented, in particular with regard to the cooperation between a thromboxane A 2 and prostaglandin I 2 receptors. The questions of desensitization and internalization of receptors are discussed. The stages of the inflammatory response and tumor progression are analyzed against the background of the disruption of the synthesis of prostanoids. Special attention is given to the significance of 15-deoxy-Δ 12,14 -prostaglandin J 2 in the regulation of the synthesis of prostanoids and its role as an anti-inflammatory agent. Ultimately, therapeutic approaches as used in various treatments are discussed in the light of the available knowledge.
Prostanoids are tissue hormones synthesized from longchain polyunsaturated fatty acids, mainly arachidonic acid (AA) (Sales et al., 2008) . Phospholipase A 2 (PLA 2 ), and to be more precise cytoplasmic phospholipase A 2 (cPLA 2 ), is the first enzyme engaged in synthesizing these compounds, as it specifically releases AA from lipids in the cell membrane, which then enters cyclooxygenase pathways ( Fig. 1) (Linkous & Yazlovitskaya; .
The two main COX isoforms are cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). Both transform AA into prostaglandin H 2 (PGH 2 ), which then again transformed by proper synthases, mainly cytosolic prostaglandin E synthase (cPGES), microsomal prostaglandin E synthase-1 (mPGES-1), microsomal prostaglandin E synthase-2 (mPGES-2), prostaglandin I synthase (PGIS), and thromboxane synthase (TxS) into prostaglandins (PGs) and thromboxanes.
The COX-1 gene is principally constitutive in function and possesses a typical, GC-rich housekeeping promoter. In contrast, the COX-2 gene resembles an early response gene. It is strongly induced by mitogenic and proinflammatory stimuli, superinduced by inhibitors of protein synthesis, and acutely regulated at both transcriptional and posttranscriptional levels (Lasa et al., 2000) .
The prostanoids of noteworthy biological significance include: prostaglandin E 2 (PGE 2 ), prostaglandin F 2α (PGF 2α ), prostaglandin D 2 (PGD 2 ), 15d-PGJ 2 , PGI 2 , and TxA 2 . PGE 2 is an important proinflammatory prostaglandin revealing antiapoptotic properties, which plays essential functions in renal physiology, the physiology of the immune system and is a developmental and growth factor associated with neoplasms (Harris, 2013) . While PGF 2α is synthesized in the uterine wall and plays a crucial role not only in the physiology of this organ, it is also an autocrine growth factor in connection with endometrial adenocarcinoma (Sales et al., 2008; Woodward et al., 2011) . A dehydrated derivative of PGD 2 (15d-PGJ 2 ) is a principal prostaglandin which inhibits prostanoid synthesis and the intensity of inflammatory reactions (Surh et al., 2011) . Other important products of arachidonic acid transformations include TxA 2 and PGI 2 , synthesized by COX-1 and COX-2, respectively (Catella-Lawson et al., 1999) . Both these prostanoids play important roles in the physiology and pathology of blood vessels (Caughey et al., 2001; Debey et al., 2003; Meyer-Kirchrath et al., 2004) . TxA 2 causes the aggregation of blood platelets and the contraction of blood vessels, whereas PGI 2 has opposite properties.
PROSTANOID SYNTHESIS IN THE COURSE OF INFLAMMATORY RESPONSE
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stance COX-2 expression increases and cPLA 2 is activated, which leads to increased PGH 2 synthesis (Murakami et al., 1997) . However, a simultaneous lack of mPGES-1 expression, transforming PGH 2 into PGE 2 , results in a coincident increase of PGD 2 synthesis (Xiao et al., 2012) . Nonetheless, the COX-2 expression in this phase does not depend on the autocrine activation by PGE 2 (Murakami et al., 1997) .
During the second phase, lasting for 12 to 48 hours after the stimulation, mPGES-1 and cPLA 2 expression takes place, which intensifies PGE 2 synthesis (Murakami et al., 1997; Xiao et al., 2012) with an unchanged synthesis of PGD 2 (Xiao et al., 2012) . Expression of COX-2 and cPLA 2 undergoes autocrine stimulation by PGE 2 , but there is no simultaneous influence of this compound on the expression of mPGES-1 (Murakami et al., 1997; Xiao et al., 2012) . The addition of inhibitors of COX-2 and/or cPLA 2 results in a simultaneously decreased expression of both enzymes (Murakami et al., 1997; Xiao et al., 2012) , while adding PGE 2 suppresses the effect of these inhibitors on the COX-2 and cPLA 2 expression (Murakami et al., 1997) . Besides, in the course of this inflammatory phase, depending on its duration, the expression of COX-2 can be hampered by 15d-PGJ 2 (Inoue et al., 2000) .
DYSREGULATION OF THE PROSTANOID SYNTHESIS PATHWAY IN NEOPLASTIC DISEASES
PGE 2 plays an important role in cancer development. It shows antiapoptotic activity and supports angiogenesis, which is why it could be a promising target in an antineoplastic therapy (Greenhough et al., 2009) .
The pathways of prostanoid synthesis tend to become dysregulated with the progression of a neoplastic disease (Table 1) . First of all, the expression of COX-2 and mPGES-1 is increased and consequently the intensity of PGE 2 production increased (Badawi & Badr, 2003; Nakanishi et al., 2008) . Apart from the amplifying inflammatory reactions, the anti-inflammatory mechanisms are dysregulated. Expression of peroxisome proliferator-activated receptor γ (PPARγ), which participates in the inhibition of inflammatory reactions, is decreased due to an increased COX-2 expression (Inoule et al., 2000) . Also the synthesis of 15d-PGJ 2 decreases as a result of the rise in mPGES-1 expression (Badawi & Badr, 2003) . The expression of mPGES-1 causes an increased PGE 2 synthesis, as mentioned above, at the cost of PGD 2 , which leads not only to the deactivation of the function of 15d-PGJ 2 , but also supports angiogenesis and the progress of neoplastic diseases (Murata et al., 2011; Davoine et al., 2013) .
The changes in the prostanoid synthesis in neoplastic cells occur along with changes in the enzymes degrading those compounds. Neoplastic cells reveal an entire lack or a decreased expression of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), a PGE 2 degrading enzyme (Wolf et al., 2006; Jang et al., 2008; Lee et al., 2013) . The mechanism underlying the expression disorders of 15-PGDH may partially result from the increased expression of COX-2 . In colorectal neoplasia a lowered expression of the prostaglandin transporter (PGT) participating in uptaking PGs is often noted, as well as an increased expression of multidrug resistanceassociated protein 4 (MRP4) taking part in the secretion of PGs from the cell (Holla et al., 2008) . Furthermore, the expression of prostaglandin receptors also increases. An increased expression of prostaglandin E 2 receptor-4 (EP 4 ) has been observed, among others, on colorectal neoplastic cells (Chell et al., 2006) . All these changes result in an increased concentration of PGE 2 in the surroundings of neoplastic cells. This causes an autocrine activation of neoplastic development and the progress of the disease.
INFLAMMATORY REACTION POSITIVE FEEDBACK LOOP INVOLVING PROSTAGLANDIN E 2
COX-2 expression is in a positive feedback loop with its products a PGE 2 and PGF 2α (Inoule et al., 2000; Sales et al., 2001; . This process is of considerable significance as far as autocrine support of inflammatory reactions and activation of neoplastic cells' growth (Sales et al., 2001; . The mechanism associated with the way prostaglandins influence COX-2 expression consists in increasing the COX-2 mRNA stability and in activating the COX-2 gene promoter (Sales et al., 2008) . Both these processes depend on the type of cells (Inoule et al., 2000; Sales et al., 2001; . PGE 2 increases the expression of COX-2 acting through its receptors, prostaglandin E 2 receptor-2 (EP 2 ) and EP 4 , which activate adenylate cyclase (AC), and this increases the concentration of cAMP in the cell (Sakuma et al., 2004) . In turn, cAMP increases the stability of COX-2 mRNA and activates COX-2 promoter by means of protein kinase A (PKA) and cAMP response element-binding protein (CREB) (Inoule et al., 2000; Sales et al., 2001; Fujino et al., 2005; Díaz-Muñoz et al., 2012) .
Activated EP 4 also activates phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K), which causes a PKA-independent signal transduction to CREB (Fujino et al., 2005) . PGE 2 also increases COX-2 expression by activating mitogen-activated protein kinase (MAPK) cascades (Faour et al., 2001; Rösch et al., 2005) . EP 4 uses PI3K to activate the extracellular-signal-regulated kinases 1 and 2 (ERK1/2) MAPK cascade, leading to increased COX-2 expression (Fujino et al., 2003; Mendez & LaPointe, 2005; Rösch et al., 2005; Sales et al., 2008) . Protein kinase C (PKC) and Ca 2+ can also participate in the activity of PGE 2 (Rösch et al., 2005) . The additionally activated EP 4 receptor, through a pathway independent of PKA, activates the p38/MAP-KAPK-2/hsp 27 cascade which is responsible for increasing the stability of COX-2 mRNA (Lasa et al., 2000; Faour et al., 2001; Rösch et al., 2005) . The stability of COX-2 mRNA is enhanced by preventing its degradation from the 3'-untranslated region of mRNA rich in AU nucleotides (Lasa et al., 2000; Faour et al., 2001) .
DEGRADATION PATHWAY OF PROSTAGLANDIN E 2
After synthesis PGE 2 , is secreted outside the cell by MRP4. During the following phase, it can be uptaken by PGT and degraded in the cytoplasm (Fig. 2) (Vezza et al., 2001 ). This particular transporter specifically transports not only PGE 2 , but also PGD 2 and PGF 2α (Vezza et al., 2001) . This is followed by the degradation of PGE 2 in the cytoplasm by 15-PGDH into an inactive 15-keto-PGE 2 form (Holla et al., 2008) . Products of COX transformations take part in regulating the PGE 2 degradation pathway.
An activated prostaglandin F 2α receptor (FP) reduces the PGT activity, and hence the uptake of prostaglandin through this transporter is reduced (Vezza et al., 2001 ). This regulation occurs through the G s protein, but is independent of AC (Vezza et al., 2001) . Additionally, the levels of COX-2 and 15-PGDH expressions are directly related to each other. Increased expression of one enzyme inhibits the expression of the other one Liu et al., 2008) . Nevertheless, the dependence between the expression of both enzymes is independent of their activity. Adding an inhibitor of one enzyme does not affect the expression of the other . The mechanism interconnecting the levels of COX-2 and 15-PGDH expression remains unclear. Most probably 15-PGDH is capable of binding 3'-untranslated region of mRNA COX-2 and, thereby destabilizing it . The reciprocal influence of COX-2 on 15-PGDH expression, is even less well understood and is still being that examined in order to understand the regulation of expression of these enzymes in neoplastic cells, where COX-2 overexpression and reduced 15-PGDH expression is observed.
MECHANISMS OF PROSTAGLANDIN F 2α -INDUCED CYCLOOXYGENASE-2 EXPRESSION
PGF 2α is yet another prostanoid with a crucial role in the regulation of the synthesis of the prostanoids discussed in this review. It increases the expression of COX-2 through its receptor (FP) and hence increases its own synthesis (Sales et al., 2008) . The autocrine activation of this enzyme's expression by PGF 2α is of considerable importance for the growth and development of endometrial adenocarcinoma. When present in concentrations reaching 100 nM PGF 2α may even activate EP 2 (Fig. 3) , leading to the same signal transduction as that caused by PGE 2 (Sales et al., 2008) . FP activates phospholipase Cβ (PLCβ) which releases inositol trisphosphate (IP 3 ) and diacylglycerol (Sales et al., 2008; Woodward et al., 2011) which activate PKC, however, this pathway will not induce the expression of COX-2 protein (Sales et al., 2008) . PGF 2α binds to FP, that caused signal transduction, which activates ERK1/2 MAPK and hence results in COX-2 expression Sales et al., 2008) .
Whilst PLCβ activates ERK1/2 MAPK by means of epidermal growth factor receptor (EGFR), which leads to expression of COX-2 (Sales et al., 2004; , it seems that also PKA also participates in transducing signals from FP to ERK1/2 MAPK (Sales et al., 2008) . As for EGFR activation, c-Src and metalloproteinases may also participate in this process . It has also been shown that the upregulation of COX-2 expression results from activating CREB and ac- tivator protein 1 (AP-1) by means of ERK1/2 MAPK (Sales et al., 2008) . The affinity of PGE 2 for FP is lower (119 nM) than its affinity for EP 2 (4.9 nM) or EP 4 (0.79 nM) (Abramovitz et al., 2000) . In concentrations reaching 100nM, PGE 2 increases the expression of COX-2 not only by its EP 2 and EP 4 receptors , but also through FP (Sales et al., 2008) . When increasing the expression of COX-2, activated EP and FP receptors act synergistically, as they activate ERK1/2 MAPK through PKA (Sales et al., 2008) . The calcium influx, dependent on IP 3 , activates Ca 2+ / calmodulin-dependent protein kinase II (CaMK-II) and ultimately the transmission of signal to Ca 2+ dependent AC isoform 3 (Abera et al., 2010) . The cross-activation of EP and FP receptor by PGE 2 and PGF 2α is crucial in neoplastic cells expressing FP as in endometrial adenocarcinoma (Sales et al., 2008; Woodward et al., 2011) . The both prostaglandins increase COX-2 expression, which results in an autocrine upregulation of their level. This, again, leads to the development and growth of the neoplasm .
15-DEOXY-Δ 12,14 -PROSTAGLANDIN J 2 AS AN ANTI-INFLAMMATORY REGULATOR OF PROSTANOID SYNTHESIS
Apart from the above-mentioned PGE 2 and PGF 2α , other prostaglandins also exert an autocrine influence on prostanoid synthesis. 15d-PGJ 2 is a prostanoid regulating the intensity of inflammatory reactions and reducing the pace of neoplastic growth and development (Surh et al., 2011) . It is formed by non-enzymatic dehydration of PGD 2 (Surh et al., 2011) .
By means of their receptors, respectively EP 2 and EP 4 , as well as the prostaglandin D 2 receptor (DP), PGE2 and PGD 2 increase the cAMP concentration and thereby enhance the expression of COX-2 protein (Sakuma et al., 2003) . After a certain period of time, however free PGD 2 becomes dehydrated to 15d-PGJ 2 , which in low concentrations reduces the expression of COX-2 protein (Surh et al., 2011) through a pathway that can be dependent or independent on the PPARγ receptor (Fig. 4 ) (Inoule et al., 2000; Sawano et al., 2002) . In cells treated with a proinflammatory factor, the activated PPARγ receptor disturbs the induction of COX-2 protein expression along various routes. In particular, it disturbs the activation of nuclear factor κB (NF-κB) (Inoule et al., 2000) . Additionally, PPARγ disrupts the activation of the AP-1 transcription factor by means of c-Jun N-terminal kinase (JNK) MAPK and binds, and thereby inactivates, CREB-binding protein (CBP)/p300 (Subbaramaiah et al., 2001) . It has also been shown that 15d-PGJ 2 inhibits signal transduction through ERK1/2 and JNK MAPK into AP-1, along a pathway independent of PPARγ receptor (Sawano et al., 2002) . Additionally, 15d-PGJ 2 inhibits the activation of NF-κB by restraining the activity of IκB kinase subunit β (IKKβ) by modifying its cysteine residues (Boyault et al., 2004) . The disrupted phosphorylation precludes the degradation of the NF-κB inhibitor: IκBα (Boyault et al., 2004) . Apart from that, 15d-PGJ 2 modifies cysteine residues in the DNA binding domain on p65 NF-κB, which leads to its inactivation (Straus et al., 2000; Boyault et al., 2004) .
The molecular mechanism of the modification of cysteine residues by 15d-PGJ 2 is well known. The arrangement of atoms in the 15d-PGJ 2 ring creates an 15d-PGJ 2 undergoes cytoplasmic uptake and activates its receptor PPARγ. This leads to inhibition of the activity of NF-κB, JNK MAPK and CBP/p300. Another pathway of 15d-PGJ 2 activity is direct inhibition of p65 NF-κB and IKKβ. Both pathways decrease COX-2 protein expression. At very large levels, 15d-PGJ 2 deactivates antioxidants containing free -SH groups. By this mechanism, it sensitizes the cells to the effects of ROS, which may lead to an increase in COX-2 protein expression.
electrophilic carbon (Straus et al., 2000) which undergoes Michael addition with cysteine residues (R-SH) (Straus et al., 2000) . The reaction with cysteines in the catalytic centre, can lead to the inactivation of an enzyme, such as IKKβ. As a consequence, this evokes the reduction of COX-2 protein expression.
Moreover, 15d-PGJ 2 affects the expression of COX-2 through mechanisms related to the synthesis of reactive oxygen species (ROS), since at low concentrations 15d-PGJ 2 activates cellular defense mechanisms against ROS and at the same time increases the concentration of antioxidants, e. g., glutathione (Koppal et al., 2000) . It also increases the level of heme oxygenase 1 expression (Koppal et al., 2000) . An increased level of antioxidants in the cell disrupts signal transduction along pathways where ROS function as second messengers. This disturbes transduction of NF-κB activation signals and activation of MAPK kinase cascades responsible for COX-2 expression (Koppal et al., 2000) .
Paradoxically, at high concentrations 15d-PGJ 2 may actually increase the expression of COX-2. In breast cancer cells, 30 μM 15d-PGJ 2 , increases the expression of COX-2 by inhibiting the activity of phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase (PTEN) (Kim et al., 2008) . This causes the activation of protein kinase B (PKB) and, signal transduction upregulating COX-2 expression (Kim et al., 2008) . 15d-PGJ 2 can also activate p38 MAPK and, by means of EGFR, also of the ERK1/2 MAPK cascade, which leads to the induction of mRNA COX-2 synthesis and also increases its stability (Kitz et al., 2011) . This mechanism resembles the route by which COX-2 expression is induced by ROS.
15d-PGJ 2 and ROS reveal a similar activity in relation to enzymes, by modifying cysteine residues in their catalytic centres. ROS create disulphide bonds or sulfenic acid (Cys-SOH), which often inhibits the activity of enzymes with a cysteine in their catalytic centre (Meng & Zhang, 2013) . When 15d-PGJ 2 reacts with a cysteine residue, it also inhibits the activity of enzymes (Straus et al., 2000; Boyault et al., 2004) . This is why the both compounds can have similar effects when present at high concentrations. Additionally, 15d-PGJ 2 inactivates glutathione and thioredoxin, sensitizing the cell to oxidative stress and second messengers, such as ROS (Shibata et al., 2003; Kim et al., 2008) . This effect may be relieved by increasing the concentration of antioxidants with free R-SH groups which react directly with 15d-PGJ 2 (Kim et al., 2008) .
The regulation of COX-2 expression is a dynamic process. On one hand it is inhibited by the PGD 2 metabolite 15d-PGJ 2 , while on the other it is activated by PGE 2 . The two prostanoids, 15d-PGJ 2 and PGE 2 , form a more complex system of interdependencies. Following the treatment of cells with an inflammatory factor, such as lipopolysaccharides (LPS), the level of PPARγ is reduced, which leads to partial deactivation of 15d-PGJ 2 and simultaneously to increased expression of COX-2 (Inoule et al., 2000) . Conversely, blocking the activity of mPGES-1, an enzyme collaborating with COX-2 in the reduction of PGE 2 , increases expression of PPARγ (Kapoor et al., 2007) . This effect is caused by signal transduction from the PGE 2 receptor to PI3K and PKB, which in turn inhibit the expression of PPARγ (Kapoor et al., 2007) .
LIGAND-MEDIATED DESENSITIZATION AND INTERNALIZATION OF RECEPTORS
Desensitization means reducing the sensitivity of a receptor in response to a prolonged exposure to a given ligand. This process plays an important role in the physiology of receptors, especially when reducing the cellular response to a particular factor, which may become too intense.
Exposure to PGE 2 results in internalization and desensitization of EP 4 receptor, whilst EP 2 maintains its sensitivity towards PGE 2 (Table 2) (Desai et al., 2000) . The C-tail plays a key role in desensitization of EP 4 , as it is phosphorylated by G protein-coupled receptor kinases (GRK) (Desai et al., 2000; Slipetz et al., 2001) . Throughout this process, PKA does not exert any influence on the EP 4 (Neuschäfer- Rube et al., 1999; Slipetz et al., 2001) . PKC is able to influence EP 4 , but this kinase is not activated by EP 4 receptor (Neuschäfer-Rube et al., 1999; Slipetz et al., 2001) . As far as the rat prostaglandin E 2 receptor-3 (EP 3 ) is concerned, EP 3α undergoes desensitization by phosphorylation dependent on GRK, whereas EP 3β does not (Neuschäfer-Rube et al., 2005) . Prostaglandin E 2 receptor-1 (EP 1 ) undergoes desensitization and internalization following of phosphorylation by PKC (Katoh et al., 1995) . Aside from EP, other receptors also undergo desensitization and internalization. Receptors for PGF 2α are present in two isoforms: FP A and FP B . PGF 2α causes internalization of FP A dependent on PKC, while FP B undergoes partial, constitutive internalization independent of the ligand, since there are no phosphorylation sites for PKC in its C-tail (Srinivasan et al., 2002) .
PGD 2 has two receptors: DP and chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2). Both these receptors have a C-tail susceptible to phosphorylation, which is essential for their internalization (Gallant et al., 2007; Schröder et al., 2009; Roy et al., 2010) . CRTH2 undergoes the internalization through phosphorylation with PKC and a GRK: GRK2, GRK5 and/or GRK6 (Roy et al., 2010) . DP internalization depends on PKC, but this kinase is not activated by DP (Gallant et al., 2007) . What is more, DP internalization depends only on GRK2 and not depend on GRK5 or GRK6 (Gallant et al., 2007) . Another difference between these two receptors lies in the fact that the internalization of CRTH2 depends on the activation of PKA (Gallant et al., 2007) . However, when this kinase is activated but CRTH2 is not, it does not result in the internalization of the receptor (Gallant et al., 2007) . The internalization of the receptors for PGD 2 also depends on arrestins: that of DP on arrestin-2 and -3, and of CRTH2 on arrestin-3 only (Gallant et al., 2007; Schröder et al., 2009; Roy et al., 2010) .
PROSTAGLANDIN SYNTHESIS COMPENSATION IN CELLS WITH DISTURBED OF CYCLOOXYGENASE PATHWAYS
Gene knockout (KO) can serve as a model for the chronic use of COX inhibitors. Dysruption of either COX gene, COX-1 or COX-2, upregulates PGE 2 synthesis in cultured cells (Table 3) (Kirtikara et al., 1998; Kanekura et al., 2002) . Cells with COX-1 or COX-2 defects show an increased expression of cPLA 2 , secreted phospholipase A 2 (sPLA 2 ), mPGES-1, as well as the second, functional COX isoform, but they also exibit by a decreased expression of mPGES-2 (Kirtikara et al., 1998; Zhang et al., 2002; Bosetti et al., 2004; Choi et al., 2006; Sandee et al., 2009) . COX-2 KO cells do not respon to proinflammatory factors (Kirtikara et al., 1998) . In the mouse brain with a COX-2 knockout it a decreased concentration of PGE 2 is observed due to a non fully compensating increased COX-1 protein expression (Bosetti et al., 2004) . In macrophages, the COX-2 defect causes an increase in the expression of 5-lipoxygenase (Zhang et al., 2002; Bosetti et al., 2004) .
Due to the production of TxA 2 by COX-1, the lack of this enzyme decreases the level of this eicosanoid as well as the level of TxS expression (Choi et al., 2006) . On the other hand, expression of COX-2 and synthesis of PGE 2 occurring under the influence of a proinflammatory factor in COX-1 KO mice was higher when compared with wild-type cells (Kirtikara et al., 1998) .
In brains of COX-1 KO mice the PGE 2 synthesis increases, as does COX-2 expression, which is caused by the activation of NF-κB (Kanekura et al., 2002; Choi et al., 2006) . This activation is due to an increased expression of NF-κB (subunits p50 and p65) and next to constant activation of IκB kinase (IKK) (Choi et al., 2006) . In contrast in COX2-KO animals, the basal level of NF-κB activaty is decreased (Rao et al., 2005) . In brain cells with COX2 KO the PGE 2 concentration is decreased, which may lead to reduced activation of NF-κB (Poligone & Baldwin, 2001; Rao et al., 2005; Choi et al., 2006) . Nevertheless, the exact mechanisms underlying the interdependence of COX-1 and COX-2 expressions require a more thorough research. It seems that the both enzymes inhibit their own expressions, and the lack of one causes a compensating increase in the expression of the second. Probably the expression of one COX isoform depends on the presence of mRNA or the protein of the other isoform. Another possibility is that products of COX pathways affect the expression of the other COX isoform.
Due to the pro-neoplastic character of the products of AA transformations by COXs and lipoxygenases, recent studies focus on the mechanisms of the inhibition of expression and activity of cPLA 2 α. In the course of inflammatory reactions, this enzyme releases AA from cell membranes lipids. Inhibiting the cPLA 2 α activity simultaneously inhibits the activity of COX and lipoxygenases. In mouse brain, cPLA2α KO leads to a reduction in COX-2 expression, which then effects in lower PGE 2 synthesis, while the expression of COX-1 and 5-lipoxygenase is unaffected (Bosetti & Weerasinghe, 2003; Sapirstein et al., 2005) . A decreased COX-2 expression may result from the inhibition of platelet-activating factor (PAF) synthesis (Serou et al., 1999; Bosetti & Weerasinghe, 2003) . PAF activates p38 and ERK1/2 MAPK, which increase the expression of COX-2 (Serou et al., 1999) . The expression of COX-2 is induced throught the proinflammatory factor. In mice with cPLA 2 α defect, the expression of COX-1 decreases after proinflammantory factor treatment, while the induction of COX-2 expression and production of PGE 2 are disturbed (Sapirstein et al., 2005) . In contrast in prostate cancer models blocking the cPLA 2 α activity leads to increased expression of COX-1 and PGE 2 production, with no changes in COX-2 expression. Additionally, the secretion of lipoxygenase transformation products is reduced. Adding 5-and/or 12-hydroxyeicosatetraenoic acid, products of lipoxygenases transformations, reduced the level of COX-1 expression and PGE 2 production (Niknami et al., 2010) .
Inhibiting the activity of mPGES-1, an enzyme engaged in the production of PGE 2 dependent on COX- 2, could be used as a therapeutic strategy in neoplasms. mPGES-1 KO disturbes the synthesis of PGE 2 and other products of COXs pathways. Enzymatic defects in mPGES-1, reducing in the production of PGE 2 may be organ specific, e.g.,. they may concern solely the brain or the stomach. Simultaneosly the production of PGI 2 , TxA 2 and PGD 2 in the digestive system is increased (Boulet et al., 2004; Elander et al., 2008) . During the stimulation of the inflammatory reaction in mPGES-1-KO mice the synthesis of TxA 2 , PGI 2 , PGF 2α and PGD 2 is increased, as is the expression of COX-2, when compared to cells with functional mPG-ES-1 (Boulet et al., 2004; Trebino et al., 2005; Brenneis et al., 2008; Elander et al., 2008) , most likely to compensate for the diminished level of PGE 2 . The compensatory mechanisms is probably not connected with changes in the expression of particular synthases, but rather with the availability of PGH 2 (Boulet et al., 2004) . Since there is no mPGES-1 expression, PGH 2 is available for transformation to proper prostanoids by other synthases. Application of mPGES-1 inhibitors in neoplastic therapy in order to limit the synthesis of PGE 2 can thus cause an increased synthesis of other proneoplastic prostanoids, and as a consequence lead to effects contrary to those intended (Elander et al., 2008) .
THE IMPACT OF THROMBOXANE A 2 AND PROSTAGLANDIN I 2 ON PROSTANOID SYNTHESIS PATHWAY
TxA 2 and PGI 2 increase COX-2 expression, which leads to increased PGI 2 synthesis in blood vessels. Upon PGI 2 binding, prostaglandin I 2 receptor (IP) upregulates cAMP synthesis, which induces COX-2 expression in the smooth muscles of blood vessels (Debey et al., 2003; Sakuma et al., 2003; Meyer-Kirchrath et al., 2004) . Increased expression of cAMP inducible early repressor occurs along with the increased COX-2 expression (Debey et al., 2003) . This transcriptional repressor binds cAMP response element-binding protein (CREB), and decreases the expression of genes including COX-2 (Debey et al., 2003) .
TxA 2 affects the expression of COX-2 by a different mechanism. Due to its instability, TxA 2 functions only locally . TxA 2 binding to thromboxane A 2 receptor (TP) activates PLCβ without affrcting cAMP concentration. (Sakuma et al., 2003; Woodward et al., 2011) . PLCβ causes the induction of COX-2 expression through ERK1/2 MAPK and thus increases the synthesis of PGE 2 and PGI 2 in blood vessel cells (Caughey et al., 2001; Chu et al., 2003) . The activation of ERK1/2 MAPK through ligand-activated TP is complex process involving PKC, PKA and PI3K (Miggin & Kinsella, 2002b) .
Expression of COX-2 and synthesis of PGI 2 can suppress the activity of TxA 2 in prolonged exposure to this thromboxane. The detailed mechanism associated with activating the expression of COX-2 is very well known. One can distinguish two isoforms of receptors for TxA 2 : thromboxane A 2 receptor isoform α (TPα) and β (TPβ). The difference between these two receptors is associated with their C-tail located at the cytoplasmic side of the cell membrane . The two isoforms of TP can be associated with diferent G proteins and can therefore activate the MAPK cascade in different manners. Among others, PKA participates in the activation of ERK1/2 MAPK by TPα, but not by TPβ . The signal transduction pathways depend on the type cell as well as the domination of the described isoforms of the receptor . Most probably the activation of TPα leads to a minimally increased cAMP concentration to the activation of PKA, whereas the second isoform TPβ has an entirely opposite influence on AC (Hirata et al., 1996) . TPα activates ERK1/2 MAPK within several minutes after TxA 2 binding, which is then followed by the deactivation of this cascade of kinases (Miggin & Kinsella, 2002b; Miyosawa et al., 2006) . While the other isoform, TPβ, activates ERK1/2 MAPK after a similar period of time, this is a long-lasting process, since an hour later the phosphorylation of ERK1/2 MAPK is still present (Miggin & Kinsella, 2002b; Miyosawa et al., 2006) .
INTERACTIONS BETWEEN THROMBOXANE A 2 AND PROSTAGLANDIN I 2 RECEPTORS
The dimerization or oligomerization of receptors plays an important role in transmitting signals from TP or IP. It does not result in proper signal transduction, but can modulate the properties not only of the receptors, but also of the signals they transmit (Wilson et al., 2004) .
Expression of both TP isoforms can lead to the formation of their heterodimer. It probably takes place immediately after the receptors are synthesized and can later cause a reduction of TPα expression . The TP heterodimer differs from the homodimers, because it produces a stronger signal in response to certain agonists (Wilson et al., 2007b) . Nevertheless, it is a simplified model, since it seems that TP receptors form both hetero-and homodimers, their oligomerization does not depend on the presence of a ligand (Laroche et al., 2005) . Individual receptors in an oligomer are connected with each other by disulphide bonds, which can be split only by reducting factors (Laroche et al., 2005) .
Apart from the fact that these two TP isoforms interact with and affect each other, they can also interact with IP. The receptors dimerization (TP and IP) and signal transduction takes place after the activation of these receptors. An activated TPα can dimerize with a nonin- activated IP and hence transmit a signal similar to that of an activated IP receptor, which means that it causes an increased cAMP concentration (Fig. 5) (Wilson et al., 2004) . Yet this process is much more intensified than the sole activity of TPα (Hirata et al., 1996; Wilson et al., 2004) . What is more, the activation of both receptors in the IP with TPα-dimer causes a synergistic activation of AC, producing a considerably higher cAMP concentration than IP ialone (Wilson et al., 2004) . The cooperation between the two receptors could be of significance as far as the activity of PGI 2 is concerned, as it will suppress the influence exerted by TxA 2 when both these prostanoids are simultaneously present a in blood vessel (Wilson et al., 2004) .
Apart from the influence exerted by IP on TP, EP 3 can also increase the intensity of signal transduction from TP. This effect most probably depends on the formation of TP oligomers with EP 3 (Reid & Kinsella, 2009 ).
DESENSITIZATION OF RECEPTORS FOR THROMBOXANE A 2 AND PROSTAGLANDIN I 2
The desensitization of receptors for TxA 2 and PGI 2 is of considerable importance in chronic exposure of cells to a large concentration of a certain prostanoid. Iloprost, a PGI 2 homologue, is capable of desensitizing the IP receptor, leading to its internalization (Nilius et al., 2000) . In addition to activating AC, IP also activates PLC, which again leads to transduction of signals to PKC (Kam et al., 2001) . This could be due to the fact that iloprost acts not only on IP itself, but also has a similar affinity towards EP 1 (Abramovitz et al., 2000; Schermuly et al., 2007) . Another possibility is that PLC is activated by IP. Upon phosphorylation of murine IP by PKA, the receptor becomes coupled to G q and G i (Lawler et al., 2001; Miggin & Kinsella, 2002a) . In contrast, human IP is not coupled to G i and it activates PLC independently of PKA action (Miggin & Kinsella, 2002a; Chow et al., 2003) . Through G q and G i , the murine IP receptor activates PLC and inhibits the activity of AC, respectively, which has been confirmed in studies using cicaprost (Lawler et al., 2001) . PLC, by means of its product diacylglycerol, then activates PKC. Nonetheless, it seems that the mechanism underlying the activation of PKC depends on the type of cell (Chow et al., 2003) . Due to these mechanisms, the ligand is capable of desensitizating IP via PKC which phosphorylates the C-tail of the receptor (Schermuly et al., 2007) . As a result IP loses the ability to activate AC. The intensity of the signal transduction from the receptor can also be reduced in another manner. Inhibition of AC isoforms 5 and 6 activity and their expression, which depends on PKA (Sobolewski et al., 2004) . This reduces capacity to increase the concentration of cAMP in response to activation occurring through receptors associated with AC. Still, this process is transient and takes place after several hours of exposure to a ligand. After one day of exposure, the initial level and activity of AC isoforms 5 and 6 is restored (Sobolewski et al., 2004) .
Activited receptors e.g., IP are once again resensitised to the ligand through endocytosis and recirculation. The described process is important in short-term regulation of receptors activity (Nilius et al., 2000) . During long-term exposure to a ligand, internalization and degradation of IP occurs, which does not depend on ist phosphorylation by PKC (Nilius et al., 2000; Smyth et al., 2000) . These processes are more intense than de novo synthesis and the recirculation of old receptors, leading to a net diminution of IP level (Nilius et al., 2000) .
The receptor for TxA 2 undergoes desensitization following phosphorylation by GRK and partially by PKC (Fig. 6) (Flannery & Spurney, 2002) . It is a complex process. TPα undergoes phosphorylation by PKC and GRK, and in turn the activity of GRK depends on the activation of endothelial nitric oxide synthase (eNOS) by this receptor and on the transmission of signals to guanylate cyclase (Kelley-Hickie et al., 2007) . Activated TPβ undergoes desensitization as well, but here mainly GRK2 and GRK3 carry outwith little involment of the phosphorylation with PKC (Kelley- Hickie & Kinsella, 2006) . After the phosphorylation, TPβ undergoes internalization, unlike TPα . The internalization of TPβ is a dynamin and arrestin-dependent process . Also palmitoylation of the C-tail of the receptor is important, as it provides a proper spatial structure .
The cross-desensitization of the TP receptor by PGI 2 is another important process taking place when both TxA 2 and PGI 2 . In blood platelets TPα is the main isoform of TP (Habib et al., 1999) . It is susceptible to desensitization by PGI 2 , which results in suppression of the activity of TxA 2 and makes blood platelets responsive only to PGI 2 . PGI 2 and also PGD 2 cause desensitization of TPα through its phosphorylation by PKA Foley et al., 2001; Wikström et al., 2008) . EP 1 is yet another receptor with an influence on TP. EP 1 activation causes the desensitization of TPα, and -to a lesser extent -also of TPβ, by PKC . The same process, occurring along the same route, is observed after FP activation (Kelley-Hickie & Kinsella, 2004) .
Transmission of the PGI 2 signal can be reduced as a result of internalization of its the receptor IP under the influence of TP activation (Wilson et al., 2007a) . Reciprocally, activated IP reduces the amount of TPα in the cell membrane. This process is independent of PKA and most probably involves heterodimerization of IP with TPα and subsequent endocytosis of the dimer (Wilson et al., 2007a) . TPα is desensitized by PKC and/or GRK. The activity of GRK towards TPα depends on receptor activation of eNOS. The activity of TPα may also be affected by activation of other prostaglandin receptors that exert their action on TPα via PKC or PKA. PKA has no effect on the ligand sensitivity of TPβ. PKC and GRK are involved only in this process. However, GRK-mediated phoshorylation of TPβ is independent of eNOS.
AUTOREGULATION OF CYCLOOXYGENASE PATHWAYS AND THE FUTURE OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
PGE 2 plays a crucial role in neoplastic processes (Greenhough et al., 2009) , therefore a preventive administration of non-steroidal anti-inflammatory drugs (NSAID) reduces the risk of multiple types of neoplasms (Ashok et al., 2011; Johannesdottir et al., 2012) . NSAIDs also seem promising anti-neoplastic drugs (Setia et al., 2012) . However, inhibiting the activity of COX-2 disturbs the synthesis of PGI 2 , therefore new therapeutic solutions are called for (CatellaLawson et al., 1999; Krotz et al., 2005) . Apart from that, inhibiting the activity of COX-2 can cause unexpected results, since the expression of this enzyme is in a negative feedback loop with 15d-PGJ 2 (Inoue et al., 2000) . This can lead to prolonged inflammation. Yet another problem is the fact that standard NSAIDs inhibit the activity of COX-2 without any influence on 15-PGDH. Therefore, modern pharmacology faces a challenge of elaboration of new NSAIDs, affecting also the expression of 15-PGDH Wakimoto et al., 2008; Tai et al., 2011) . In order to accomplish this task, it is essential to fully unrevel the mechanisms of mutual the dependence of COX-2 and 15-PGDH by detailed studies of the autoregulation of cyclooxygenase pathways.
Apart from inhibiting the activity of COX-2, it is also possible to inhibit the activity of mPGES-1, thereby inhibiting PGE 2 synthesis. In colorectal cancer such an approach decreases mass and a reduces the number of polyps formed (Nakanishi et al., 2008) . Nonetheless, inhibiting the expression and activity of mPGES-1 may lead to a more intense transformation of PGH 2 into TxA 2 , PGI 2 , and PGF 2α (Trebino et al., 2005; Brenneis et al., 2008; Elander et al., 2008) , which stimulate neoplastic cells. That is why, instead of having an anti-neoplastic effect, mPG-ES-1 inhibitors can actually increased the volume and number of neoplasmatic lesions due to an enhanced production of other eicosanoids (Elander et al., 2008) .
Another therapeutic approach consists in using antagonists of EP 2 and EP 4 receptors (Kitamura et al., 2003) , due to which a neoplastic cell will produce and secrete large amounts of PGE 2 , but the autocrine response to this prostanoid will be disrupted, and this will in turn lead to increased apoptosis and inhibition of cellular divisions.
A chronic administration of specific COX-1 or COX-2 inhibitors or a decreased expression of these enzymes can produce unexpected results. It may increase the level of PGE 2 , which is illustrated perfectly by the example of mice with KO of a selected COX gene (Bosetti et al., 2004; Choi et al., 2006; Sandee et al., 2009) . Inhibiting the expression of COX-2 leads to a compensating increase in the expression of COX-1, which again results in an increased production of PGE 2 (Sandee et al., 2009) . Further studies should provide thorough knowledge of the dependence underlying the expression of both isoforms of COX, in order to understand the action and to develop medication capable of influencing the expression of these enzymes.
It has been demonstrated that non-specific inhibitors of COXs in moderate doses can decrease production of TxA 2 by blood platelets, in addition to a having therapeutic effect in the thrombosis (Caughey et al., 2001; Krotz et al., 2005) . COX-1 is the main isoform of COX in blood vessels and this particular enzyme is the one that undergoes inhibition, while specific inhibitors of COX-2 result in a decreased production of PGI 2 and hence increase the aggregation of blood platelets (Catella-Lawson et al., 1999; Krotz et al., 2005) .
Instead of inhibiting the synthesis of a single prostanoid, it is possible to use another eicosanoid which has an opposite effect. The use of PGI 2 analogues has shown therapeutic effects in patients suffering from thrombosis. In this such an approach balances the effect of TxA 2 without causing the negative consequences connected with its absence (Wilson et al., 2004) .
